First Trust Nasdaq Pharmaceuticals ETF
FTXH
13 hedge funds and large institutions have $7.57M invested in First Trust Nasdaq Pharmaceuticals ETF in 2020 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
161% more capital invested
Capital invested by funds: $2.9M → $7.57M (+$4.67M)
63% more funds holding
Funds holding: 8 → 13 (+5)
10.4% more ownership
Funds ownership: 49.36% → 59.76% (+10%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAWM
J. Arnold Wealth Management
Youngstown,
Ohio
|
+$2.18M |
| 2 |
LPL Financial
San Diego,
California
|
+$1.26M |
| 3 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$379K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$364K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$60.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$167K |
| 2 |
SMFS
Squar Milner Financial Services
Irvine,
California
|
-$109K |
FTXH Hedge Fund Activity: Q2 2020 in Review
13 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q2 2020, worth a combined $7.57M — up 161% from $2.9M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new FTXH positions and 1 closed out — a net gain of 5 holders — while 5 added to existing stakes and 1 trimmed.
The largest buyer was J. Arnold Wealth Management, adding an estimated $2.18M. The largest seller was Susquehanna International Group, cutting an estimated $167K.
- 13 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q2 2020, up from 8 in Q1 2020.
- Funds reported $7.57M of First Trust Nasdaq Pharmaceuticals ETF stock for Q2 2020, up 161% quarter-over-quarter.
- 6 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q2 2020 and 1 closed out, a net change of +5 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q2 2020 was J. Arnold Wealth Management, an estimated $2.18M added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q2 2020 was Susquehanna International Group, an estimated $167K sold.
Based on aggregated 13F filings for Q2 2020.